Ketchum names new healthcare head

Share this article:
Ketchum named Ann Moravick EVP and director, global healthcare and brand advocacy.
Moravick joins the company from Publicis Consultants PR, where she was US CEO.

She is charged with spearheading the growth and expanding the global reach of the agency's healthcare practice by bridging the work of its international offices, and reports to partners Dale Bornstein, director, global practices, and Barri Rafferty, director, New York.

Before Publicis, Moravick spent 18 years at Manning, Selvage & Lee in various roles.

Bornstein said her “integrated approach to healthcare and brand advocacy will serve the evolving needs of our clients and further differentiate Ketchum's healthcare practice from others in the industry. With Ann's diverse experience, both in the US and in Europe, she will prove to be an asset to our healthcare clients as they navigate the global markets.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...